Latanoprost does not affect immune privilege of corneal allografts

Experimental Eye Research
Mingcong WangJunko Hori

Abstract

The present study determined whether topical latanoprost, a prostaglandin (PG) F(2alpha) analog, influences the induction of anterior chamber-associated immune deviation (ACAID), corneal neovascularization (NV) or survival of corneal allografts in mice. BALB/c mice received topical latanoprost or PGE(2) once or multiple times daily starting 4 weeks prior to or the day of anterior chamber injection of C57BL/6 splenocytes. Induction of allo-specific ACAID was assessed by ear challenge with C57BL/6 splenocytes 1 week after subcutaneous immunization. In a separate experiment, orthotopic corneal transplantation was performed using C57BL/6 mice as donors and BALB/c mice as recipients. Recipients were randomized in a masked fashion to receive topical latanoprost or PGE(2). Graft fate was assessed clinically under surgical microscopy. Presence of MHC class II(+) CD11c(+) or CD11b(+) cells in normal BALB/c mouse eyes following latanoprost or PGE(2) administration was assessed immunohistochemically. Control mice received topical 20% dimethyl sulfoxide or no treatment. Allo-specific ACAID was induced after 2 or 6 weeks of once daily treatment with latanoprost, and was induced even after 6 weeks of multiple treatments with latanoprost. Con...Continue Reading

References

Mar 1, 1990·Survey of Ophthalmology·S E Wilson, H E Kaufman
Nov 1, 1993·Ophthalmology·H M BoisjolyR Roy
Mar 26, 1998·International Journal for Parasitology·A Daugschies, B Ruttkowski
Apr 29, 1998·Journal of the American Optometric Association·I B Gaddie, D W Bennett
Jul 31, 1998·American Journal of Ophthalmology·R D FechtnerR Warwar
Oct 27, 1998·Ophthalmology·J J IngW M Bourne
Apr 7, 1999·Progress in Retinal and Eye Research·J W Streilein
Mar 30, 2001·The Journal of Biological Chemistry·H ShengR N DuBois
Apr 28, 2001·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·S SaccàM Rolando
Sep 25, 2001·The British Journal of Ophthalmology·C Lindén, A Alm
Mar 28, 2002·Cornea·Edimar Tiago FrançaFlavio Jaime Rocha
Nov 12, 2002·International Reviews of Immunology·Joan Stein-Streilein, J Wayne Streilein
Jan 31, 2003·Investigative Ophthalmology & Visual Science·Pedram HamrahM Reza Dana
Dec 12, 2003·Nature Reviews. Immunology·J Wayne Streilein
Jun 30, 2004·Investigative Ophthalmology & Visual Science·Jonathan G CrowstonRobert N Weinreb
Sep 29, 2004·Investigative Ophthalmology & Visual Science·Jonathan G CrowstonRobert N Weinreb

❮ Previous
Next ❯

Citations

May 11, 2010·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·G GeerlingT Klink
Jun 11, 2008·Immunology·Holly R ChinneryPaul G McMenamin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.